| In a recent publication in Science, Adrian Hayday and colleagues discussed the mechanisms of gamma delta (γδ) T cell immunotherapy and explored ongoing clinical applications.
The review highlights the capability of γδ T cells to target a wide range of tumours with low mutagenic loads among patients of diverse ethnicities, making them highly attractive candidates for tackling cancer. Further, γδ T cells can bridge innate and adaptive immunity to naturally discriminate cancers from healthy tissues and support wound healing.
γδ T cell–based clinical trials, including off-the-shelf adoptive cell therapy and agonist antibodies, are yielding promising results in safety and efficacy.
Founded on Adrian’s pioneering research into γδ T cells, our spin-out Gamma Delta Therapeutics has been harnessing γδ T cells to improve patient outcomes and survival rates throughout the past eight years.
|
